InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...

Bausch + Lomb (BLCO) announced an affiliate has acquired Whitecap Biosciences which is currently developing two innovative therapies for ...

City Therapeutics and Bausch + Lomb have entered into a strategic collaboration focused on the development of an RNA ...

Bausch + Lomb moved to bolster the eye-care company's pipeline of clinical-stage offerings with the acquisition of Whitecap Biosciences, a firm developing two therapies for potential use in glaucoma ...

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Bausch + Lomb Corporation (NYSE:BLCO) stands against the other best ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target ...

Jersey City-based Character Biosciences has announced a collaboration with Bausch + Lomb to develop innovative treatments for ...